Physiochemical  ||| S:0 E:15 ||| JJ
property  ||| S:15 E:24 ||| NN
space  ||| S:24 E:30 ||| NN
distribution  ||| S:30 E:43 ||| NN
among  ||| S:43 E:49 ||| IN
human  ||| S:49 E:55 ||| JJ
metabolites ||| S:55 E:66 ||| NN
,  ||| S:66 E:68 ||| ,
drugs  ||| S:68 E:74 ||| NNS
and  ||| S:74 E:78 ||| CC
toxins  ||| S:78 E:85 ||| VBG
The  ||| S:85 E:89 ||| DT
current  ||| S:89 E:97 ||| JJ
approach  ||| S:97 E:106 ||| NN
to  ||| S:106 E:109 ||| TO
screen  ||| S:109 E:116 ||| VB
for  ||| S:116 E:120 ||| IN
drug-like  ||| S:120 E:130 ||| JJ
molecules  ||| S:130 E:140 ||| NN
is  ||| S:140 E:143 ||| VBZ
to  ||| S:143 E:146 ||| TO
sieve  ||| S:146 E:152 ||| VB
for  ||| S:152 E:156 ||| IN
molecules  ||| S:156 E:166 ||| NNS
with  ||| S:166 E:171 ||| IN
biochemical  ||| S:171 E:183 ||| JJ
properties  ||| S:183 E:194 ||| NNS
suitable  ||| S:194 E:203 ||| JJ
for  ||| S:203 E:207 ||| IN
desirable  ||| S:207 E:217 ||| JJ
pharmacokinetics  ||| S:217 E:234 ||| NN
and  ||| S:234 E:238 ||| CC
reduced  ||| S:238 E:246 ||| JJ
toxicity ||| S:246 E:254 ||| NN
,  ||| S:254 E:256 ||| ,
using  ||| S:256 E:262 ||| VBG
predominantly  ||| S:262 E:276 ||| RB
biophysical  ||| S:276 E:288 ||| JJ
properties  ||| S:288 E:299 ||| NNS
of  ||| S:299 E:302 ||| IN
chemical  ||| S:302 E:311 ||| JJ
compounds ||| S:311 E:320 ||| NN
,  ||| S:320 E:322 ||| ,
based  ||| S:322 E:328 ||| VBN
on  ||| S:328 E:331 ||| IN
empirical  ||| S:331 E:341 ||| JJ
rules  ||| S:341 E:347 ||| NNS
such  ||| S:347 E:352 ||| JJ
as  ||| S:352 E:355 ||| IN
Lipinski ||| S:355 E:363 ||| NNP
's  ||| S:363 E:366 ||| POS
rule  ||| S:366 E:371 ||| NN
of  ||| S:371 E:374 ||| IN
five  ||| S:374 E:379 ||| CD
( ||| S:379 E:380 ||| -LRB-
Ro5 ||| S:380 E:383 ||| NNP
) ||| S:383 E:384 ||| -RRB-
.  ||| S:384 E:386 ||| .
For  ||| S:386 E:390 ||| IN
over  ||| S:390 E:395 ||| IN
a  ||| S:395 E:397 ||| DT
decade ||| S:397 E:403 ||| NN
,  ||| S:403 E:405 ||| ,
Ro5  ||| S:405 E:409 ||| NNP
has  ||| S:409 E:413 ||| VBZ
been  ||| S:413 E:418 ||| VBN
applied  ||| S:418 E:426 ||| VBN
to  ||| S:426 E:429 ||| TO
combinatorial  ||| S:429 E:443 ||| VB
compounds ||| S:443 E:452 ||| NNS
,  ||| S:452 E:454 ||| ,
drugs  ||| S:454 E:460 ||| NNS
and  ||| S:460 E:464 ||| CC
ligands ||| S:464 E:471 ||| NN
,  ||| S:471 E:473 ||| ,
in  ||| S:473 E:476 ||| IN
the  ||| S:476 E:480 ||| DT
search  ||| S:480 E:487 ||| NN
for  ||| S:487 E:491 ||| IN
suitable  ||| S:491 E:500 ||| JJ
lead  ||| S:500 E:505 ||| NN
compounds ||| S:505 E:514 ||| NN
.  ||| S:514 E:516 ||| .
Unfortunately ||| S:516 E:529 ||| RB
,  ||| S:529 E:531 ||| ,
till  ||| S:531 E:536 ||| IN
date ||| S:536 E:540 ||| NN
,  ||| S:540 E:542 ||| ,
a  ||| S:542 E:544 ||| DT
clear  ||| S:544 E:550 ||| JJ
distinction  ||| S:550 E:562 ||| NN
between  ||| S:562 E:570 ||| IN
drugs  ||| S:570 E:576 ||| NNS
and  ||| S:576 E:580 ||| CC
non-drugs  ||| S:580 E:590 ||| NNP
has  ||| S:590 E:594 ||| VBZ
not  ||| S:594 E:598 ||| RB
been  ||| S:598 E:603 ||| VBN
achieved ||| S:603 E:611 ||| VBN
.  ||| S:611 E:613 ||| .
The  ||| S:613 E:617 ||| DT
current  ||| S:617 E:625 ||| JJ
trend  ||| S:625 E:631 ||| NN
is  ||| S:631 E:634 ||| VBZ
to  ||| S:634 E:637 ||| TO
seek  ||| S:637 E:642 ||| VB
out  ||| S:642 E:646 ||| RP
drugs  ||| S:646 E:652 ||| NNS
which  ||| S:652 E:658 ||| WDT
show  ||| S:658 E:663 ||| VBP
metabolite-likeness ||| S:663 E:682 ||| JJ
.  ||| S:682 E:684 ||| .
In  ||| S:684 E:687 ||| IN
identifying  ||| S:687 E:699 ||| VBG
similar  ||| S:699 E:707 ||| JJ
physicochemical  ||| S:707 E:723 ||| JJ
characteristics ||| S:723 E:738 ||| NNS
,  ||| S:738 E:740 ||| ,
compounds  ||| S:740 E:750 ||| NNS
have  ||| S:750 E:755 ||| VBP
usually  ||| S:755 E:763 ||| RB
been  ||| S:763 E:768 ||| VBN
clustered  ||| S:768 E:778 ||| VBN
based  ||| S:778 E:784 ||| VBN
on  ||| S:784 E:787 ||| IN
some  ||| S:787 E:792 ||| DT
characteristic ||| S:792 E:806 ||| NN
,  ||| S:806 E:808 ||| ,
to  ||| S:808 E:811 ||| TO
reduce  ||| S:811 E:818 ||| VB
the  ||| S:818 E:822 ||| DT
search  ||| S:822 E:829 ||| NN
space  ||| S:829 E:835 ||| NN
presented  ||| S:835 E:845 ||| VBN
by  ||| S:845 E:848 ||| IN
large  ||| S:848 E:854 ||| JJ
molecular  ||| S:854 E:864 ||| JJ
datasets ||| S:864 E:872 ||| NN
.  ||| S:872 E:874 ||| .
This  ||| S:874 E:879 ||| DT
paper  ||| S:879 E:885 ||| NN
examines  ||| S:885 E:894 ||| VBZ
the  ||| S:894 E:898 ||| DT
similarity  ||| S:898 E:909 ||| NN
of  ||| S:909 E:912 ||| IN
current  ||| S:912 E:920 ||| JJ
drug  ||| S:920 E:925 ||| NN
molecules  ||| S:925 E:935 ||| NNS
with  ||| S:935 E:940 ||| IN
human  ||| S:940 E:946 ||| JJ
metabolites  ||| S:946 E:958 ||| NN
and  ||| S:958 E:962 ||| CC
toxins ||| S:962 E:968 ||| NN
,  ||| S:968 E:970 ||| ,
using  ||| S:970 E:976 ||| VBG
a  ||| S:976 E:978 ||| DT
range  ||| S:978 E:984 ||| NN
of  ||| S:984 E:987 ||| IN
computed  ||| S:987 E:996 ||| JJ
molecular  ||| S:996 E:1006 ||| JJ
descriptors  ||| S:1006 E:1018 ||| NN
as  ||| S:1018 E:1021 ||| IN
well  ||| S:1021 E:1026 ||| RB
as  ||| S:1026 E:1029 ||| IN
the  ||| S:1029 E:1033 ||| DT
effect  ||| S:1033 E:1040 ||| NN
of  ||| S:1040 E:1043 ||| IN
comparison  ||| S:1043 E:1054 ||| NN
to  ||| S:1054 E:1057 ||| TO
clustered  ||| S:1057 E:1067 ||| VB
data  ||| S:1067 E:1072 ||| NNS
compared  ||| S:1072 E:1081 ||| VBN
to  ||| S:1081 E:1084 ||| TO
searches  ||| S:1084 E:1093 ||| NNS
against  ||| S:1093 E:1101 ||| IN
complete  ||| S:1101 E:1110 ||| JJ
datasets ||| S:1110 E:1118 ||| NN
.  ||| S:1118 E:1120 ||| .
We  ||| S:1120 E:1123 ||| PRP
have  ||| S:1123 E:1128 ||| VBP
carried  ||| S:1128 E:1136 ||| VBN
out  ||| S:1136 E:1140 ||| RP
statistical  ||| S:1140 E:1152 ||| JJ
and  ||| S:1152 E:1156 ||| CC
substructure  ||| S:1156 E:1169 ||| JJ
functional  ||| S:1169 E:1180 ||| JJ
group  ||| S:1180 E:1186 ||| NN
analyses  ||| S:1186 E:1195 ||| NNS
of  ||| S:1195 E:1198 ||| IN
three  ||| S:1198 E:1204 ||| CD
datasets ||| S:1204 E:1212 ||| NN
,  ||| S:1212 E:1214 ||| ,
namely  ||| S:1214 E:1221 ||| RB
human  ||| S:1221 E:1227 ||| JJ
metabolites ||| S:1227 E:1238 ||| NN
,  ||| S:1238 E:1240 ||| ,
drugs  ||| S:1240 E:1246 ||| NNS
and  ||| S:1246 E:1250 ||| CC
toxin  ||| S:1250 E:1256 ||| NN
molecules ||| S:1256 E:1265 ||| NNS
.  ||| S:1265 E:1267 ||| .
The  ||| S:1267 E:1271 ||| DT
distributions  ||| S:1271 E:1285 ||| NNS
of  ||| S:1285 E:1288 ||| IN
various  ||| S:1288 E:1296 ||| JJ
molecular  ||| S:1296 E:1306 ||| JJ
descriptors  ||| S:1306 E:1318 ||| NN
were  ||| S:1318 E:1323 ||| VBD
investigated ||| S:1323 E:1335 ||| VBN
.  ||| S:1335 E:1337 ||| .
Our  ||| S:1337 E:1341 ||| PRP$
analyses  ||| S:1341 E:1350 ||| JJ
show  ||| S:1350 E:1355 ||| NN
that ||| S:1355 E:1359 ||| IN
,  ||| S:1359 E:1361 ||| ,
although  ||| S:1361 E:1370 ||| IN
the  ||| S:1370 E:1374 ||| DT
three  ||| S:1374 E:1380 ||| CD
groups  ||| S:1380 E:1387 ||| NNS
are  ||| S:1387 E:1391 ||| VBP
distinct ||| S:1391 E:1399 ||| JJ
,  ||| S:1399 E:1401 ||| ,
present-day  ||| S:1401 E:1413 ||| JJ
drugs  ||| S:1413 E:1419 ||| NNS
are  ||| S:1419 E:1423 ||| VBP
closer  ||| S:1423 E:1430 ||| JJR
to  ||| S:1430 E:1433 ||| TO
toxin  ||| S:1433 E:1439 ||| NN
molecules  ||| S:1439 E:1449 ||| NNS
than  ||| S:1449 E:1454 ||| IN
to  ||| S:1454 E:1457 ||| TO
metabolites ||| S:1457 E:1468 ||| VB
.  ||| S:1468 E:1470 ||| .
Furthermore ||| S:1470 E:1481 ||| RB
,  ||| S:1481 E:1483 ||| ,
these  ||| S:1483 E:1489 ||| DT
distributions  ||| S:1489 E:1503 ||| NNS
are  ||| S:1503 E:1507 ||| VBP
quite  ||| S:1507 E:1513 ||| RB
similar  ||| S:1513 E:1521 ||| JJ
for  ||| S:1521 E:1525 ||| IN
both  ||| S:1525 E:1530 ||| DT
clustered  ||| S:1530 E:1540 ||| JJ
data  ||| S:1540 E:1545 ||| NNS
as  ||| S:1545 E:1548 ||| IN
well  ||| S:1548 E:1553 ||| RB
as  ||| S:1553 E:1556 ||| IN
complete  ||| S:1556 E:1565 ||| JJ
or  ||| S:1565 E:1568 ||| CC
unclustered  ||| S:1568 E:1580 ||| JJ
datasets ||| S:1580 E:1588 ||| NN
.  ||| S:1588 E:1590 ||| .
The  ||| S:1590 E:1594 ||| DT
property  ||| S:1594 E:1603 ||| NN
space  ||| S:1603 E:1609 ||| NN
occupied  ||| S:1609 E:1618 ||| VBD
by  ||| S:1618 E:1621 ||| IN
metabolites  ||| S:1621 E:1633 ||| NN
is  ||| S:1633 E:1636 ||| VBZ
dissimilar  ||| S:1636 E:1647 ||| VBN
to  ||| S:1647 E:1650 ||| TO
that  ||| S:1650 E:1655 ||| DT
of  ||| S:1655 E:1658 ||| IN
drugs  ||| S:1658 E:1664 ||| NNS
or  ||| S:1664 E:1667 ||| CC
toxin  ||| S:1667 E:1673 ||| NN
molecules ||| S:1673 E:1682 ||| NNS
,  ||| S:1682 E:1684 ||| ,
with  ||| S:1684 E:1689 ||| IN
current  ||| S:1689 E:1697 ||| JJ
drugs  ||| S:1697 E:1703 ||| NNS
showing  ||| S:1703 E:1711 ||| VBG
greater  ||| S:1711 E:1719 ||| JJR
similarity  ||| S:1719 E:1730 ||| NN
to  ||| S:1730 E:1733 ||| TO
toxins  ||| S:1733 E:1740 ||| VB
than  ||| S:1740 E:1745 ||| IN
to  ||| S:1745 E:1748 ||| TO
metabolites ||| S:1748 E:1759 ||| VB
.  ||| S:1759 E:1761 ||| .
Additionally ||| S:1761 E:1773 ||| RB
,  ||| S:1773 E:1775 ||| ,
empirical  ||| S:1775 E:1785 ||| JJ
rules  ||| S:1785 E:1791 ||| NNS
like  ||| S:1791 E:1796 ||| IN
Ro5  ||| S:1796 E:1800 ||| NNP
can  ||| S:1800 E:1804 ||| MD
be  ||| S:1804 E:1807 ||| VB
refined  ||| S:1807 E:1815 ||| VBN
to  ||| S:1815 E:1818 ||| TO
identify  ||| S:1818 E:1827 ||| VB
drugs  ||| S:1827 E:1833 ||| NNS
or  ||| S:1833 E:1836 ||| CC
drug-like  ||| S:1836 E:1846 ||| JJ
molecules  ||| S:1846 E:1856 ||| NNS
that  ||| S:1856 E:1861 ||| WDT
are  ||| S:1861 E:1865 ||| VBP
clearly  ||| S:1865 E:1873 ||| RB
distinct  ||| S:1873 E:1882 ||| JJ
from  ||| S:1882 E:1887 ||| IN
toxic  ||| S:1887 E:1893 ||| JJ
compounds  ||| S:1893 E:1903 ||| NN
and  ||| S:1903 E:1907 ||| CC
more  ||| S:1907 E:1912 ||| RBR
metabolite-like ||| S:1912 E:1927 ||| JJ
.  ||| S:1927 E:1929 ||| .
The  ||| S:1929 E:1933 ||| DT
inclusion  ||| S:1933 E:1943 ||| NN
of  ||| S:1943 E:1946 ||| IN
human  ||| S:1946 E:1952 ||| JJ
metabolites  ||| S:1952 E:1964 ||| NN
in  ||| S:1964 E:1967 ||| IN
this  ||| S:1967 E:1972 ||| DT
study  ||| S:1972 E:1978 ||| NN
provides  ||| S:1978 E:1987 ||| VBZ
a  ||| S:1987 E:1989 ||| DT
deeper  ||| S:1989 E:1996 ||| JJR
insight  ||| S:1996 E:2004 ||| NN
into  ||| S:2004 E:2009 ||| IN
metabolite ||| S:2009 E:2019 ||| CD
/ ||| S:2019 E:2020 ||| CD
drug ||| S:2020 E:2024 ||| NN
/ ||| S:2024 E:2025 ||| CD
toxin-like  ||| S:2025 E:2036 ||| JJ
properties  ||| S:2036 E:2047 ||| NNS
and  ||| S:2047 E:2051 ||| CC
will  ||| S:2051 E:2056 ||| MD
also  ||| S:2056 E:2061 ||| RB
prove  ||| S:2061 E:2067 ||| VB
to  ||| S:2067 E:2070 ||| TO
be  ||| S:2070 E:2073 ||| VB
valuable  ||| S:2073 E:2082 ||| JJ
in  ||| S:2082 E:2085 ||| IN
the  ||| S:2085 E:2089 ||| DT
prediction  ||| S:2089 E:2100 ||| NN
or  ||| S:2100 E:2103 ||| CC
optimization  ||| S:2103 E:2116 ||| NN
of  ||| S:2116 E:2119 ||| IN
small  ||| S:2119 E:2125 ||| JJ
molecules  ||| S:2125 E:2135 ||| NNS
as  ||| S:2135 E:2138 ||| IN
ligands  ||| S:2138 E:2146 ||| NN
for  ||| S:2146 E:2150 ||| IN
therapeutic  ||| S:2150 E:2162 ||| JJ
applications ||| S:2162 E:2174 ||| NNS
.  ||| S:2174 E:2176 ||| .
